CEACAM5 and neoplasm: CEA was also one of the first markers assayed in patients with breast cancer, but now, due to its low sensitivity and specificity, the National Academy of Clinical Biochemistry (NACB) and the European Group on Tumor Markers (EGTM) do not recommend its determination in these patients [27, 28].